Receptor News and Research

RSS

Scientists map EGFRvIII mutant that causes brain cancer

A team of Ludwig Cancer Research scientists has mapped out how a mutant version of the epidermal growth factor receptor (EGFR) known as EGFRvIII specifically drives critical processes that alter the reading of the genome to fuel the growth of the brain cancer glioblastoma multiforme (GBM) and--most important--how each process is linked to the other.

9 Oct 2015

Researchers reveal new subtypes of invasive lobular carcinoma

Researchers from the UNC Lineberger Comprehensive Cancer Center and other academic centers have revealed new subtypes of invasive lobular carcinoma, the second most commonly diagnosed invasive breast cancer type. The findings could lead to personalized treatment approaches for the disease.

9 Oct 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.

9 Oct 2015

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer.

8 Oct 2015

Researchers identify completely new information on how cancer cells internally transmit signals

A new study from the University of Turku, Finland, shows that intracellular receptor signalling sustains cancer cells that have detached from the surrounding tissue. When the signalling is prevented, the cells cannot spread to other parts of the body. This significant research result influences how cancer research is directed in the future.

8 Oct 2015

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

While high levels of the satiety hormone leptin don't help obese individuals lose weight, they do appear to directly contribute to their cardiovascular disease, researchers report.

8 Oct 2015

Smoking cessation medication 46% effective in women

The most effective prescription drug used to quit smoking initially helps women more than men, according to a Yale School of Medicine study. The study, published Oct. 7 by the journal Nicotine and Tobacco Research, found that varenicline, marketed as Chantix, was more effective earlier in women, and equally effective in women and men after one year.

8 Oct 2015

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.

7 Oct 2015

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes.

7 Oct 2015

Researchers study effect of immune tolerance on certain cancer risks

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. "But we didn't know whether this is a consequence of an aggressive tumor or rather its cause," says Rudolf Kaaks, epidemiologist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

Rhythmic expression of key genes is essential for maintaining proper timekeeping of the body's clock. In addition, rhythmic degradation of clockwork proteins is also crucial. However, surprisingly, researchers know little about these specific processes.

7 Oct 2015

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Researchers from Brigham and Women's Hospital and the University of Murcia, Spain, have shed new light on why people who carry a common genetic mutation may be more at risk for developing type 2 diabetes. By carefully studying healthy subjects, researchers were able to chart the effect of melatonin supplements on blood sugar control.

7 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

Dopamine transmission mediated by D1 receptors essential for controlling movements in Parkinson's disease

Dopamine deficiency in the basal ganglia (a set of subcortical structures) causes severe motor dysfunctions, such as slowness of movements (bradykinesia), as observed in Parkinson's disease. Dopamine binds D1 and D2 receptors that are expressed in the nerve cells of the striatum (a structure of the basal ganglia), and exerts different effects on the nerve cells. However, how dopamine controls through these receptors the information flow in the basal ganglia and voluntary movements is still not clear.

6 Oct 2015

IU-led scientists discover new gene that increases Alzheimer's disease risk

In a newly published study, a multi-institutional team led by scientists at the Indiana University School of Medicine have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains of Alzheimer's patients and older adults at risk for the disease.

6 Oct 2015

UT Southwestern announces launch of new health initiative

UT Southwestern Medical Center today announced the launch of "Call Out Cancer," a new health initiative designed to promote awareness, early detection, and prevention of all types of cancer.

6 Oct 2015

Key neurotransmitter receptor may be a potential target for individualised Autism Spectrum Disorder treatment

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered a significant—and potentially treatable—relationship between a chemical that helps transmit signals in the brain and genetic mutations present in a subset of individuals with autism spectrum disorder.

5 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Receptor News and Research

Scientists map EGFRvIII mutant that causes brain cancer

Researchers reveal new subtypes of invasive lobular carcinoma

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Researchers identify completely new information on how cancer cells internally transmit signals

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

Smoking cessation medication 46% effective in women

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Researchers study effect of immune tolerance on certain cancer risks

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Dopamine transmission mediated by D1 receptors essential for controlling movements in Parkinson's disease

IU-led scientists discover new gene that increases Alzheimer's disease risk

UT Southwestern announces launch of new health initiative

Key neurotransmitter receptor may be a potential target for individualised Autism Spectrum Disorder treatment

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News